Last reviewed · How we verify
NCT06785545
Urinary CA19-9 Level in the Differential Diagnosis of Neurogenic and Non-Neurogenic Lower Urinary Tract Dysfunction in Children
NA trial testing CA19-9 in Lower Urinary Track Symptoms in 100 participants. Status unknown.
12 November 2024
Quick facts
| Lead sponsor | Marmara University |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | screening |
| Enrollment | 100 |
| Start date | 1 January 2024 |
| Primary completion | 12 November 2024 |
| Estimated completion | 30 January 2025 |
| Sites | 1 location across Turkey (Türkiye) |
Drugs / interventions tested
- CA19-9
Conditions studied
- Lower Urinary Track Symptoms — all drugs for Lower Urinary Track Symptoms →
Sponsor
Marmara University
Who can join
Adults 5 to 18, any sex, with Lower Urinary Track Symptoms. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
It has been shown in the literature that urinary CA19-9 levels are associated with the degree of hydronephrosis and the anteroposterior diameter of the renal pelvis. Additionally, this marker has been reported as a potential indicator of kidney damage related to obstructive uropathies. A study conducted in our clinic, which has yet to be published, investigated CA19-9 levels in children with hydronephrosis of different etiologies. It found a statistically significant difference in CA19-9 levels between children with neurogenic and non-neurogenic lower urinary tract (LUT) dysfunction (Evaluation of Spot Urine Carbohydrate Antigen 19-9, Sodium, Potassium, and Creatinine Levels as Biomarkers for Differential Diagnosis of Hydronephrosis and Detection of Kidney Damage in Children Aged 0-16: A Prospective Study, Kütükoğlu et al.). Based on this, the hypothesis was formulated that urinary CA19-9 might be a potential biomarker for indicating neurological deficits in children presenting with LUT symptoms. Therefore, this study aimed to compare CA19-9 levels in a larger group of children with neurogenic and non-neurogenic LUT dysfunction.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06785545
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Lower Urinary Track Symptoms
Currently open trials in the same condition.
- NCT07377929 — Intradetrusor Onabotulinumtoxin A (Botox) at the Time of Transurethral Resection of the Prostate or Transurethral Waterj · recruiting
- NCT06944145 — New Treatment Strategies and Epigenetic Biomarker for Management of Benign Prostatic Hyperplasia · Phase 2 · recruiting
- NCT06834152 — Online Adaptive Stereotactic Body Radiotherapy for Localized Prostate Cancer (X-SMILE) · recruiting
Other Marmara University trials
Trials by the same sponsor.
- NCT07533734 — The Effects of an Augmented Reality-Based Mirror Therapy System in Patients With Stroke · NA · not yet recruiting
- NCT07474181 — Simulation-Based Training for Urinary Catheterization Skills in Nursing Students · NA · not yet recruiting
- NCT07486349 — Shoulder Pericapsular Block Versus Interscalene Block in Arthroscopic Shoulder Surgery · NA · not yet recruiting
- NCT07468110 — Evaluation Of The Relationship Between The Conut Score And Balance And Functional Status In Patients With Chronic Stroke · recruiting
- NCT07468097 — The Impact of Metabolic Status on Pain and Central Sensitization in Women With Lipedema: A Cross-Sectional Observational · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06785545 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Marmara University
- Last refreshed: 21 January 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06785545.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing